Scholarlink

<p>Gynecological cancer poses a serious threat to women’s health. Despite significant advances in immunotherapy and targeted therapeutic strategies for gynecological cancers, substantial challenges persist, including limited response rates, inevitable resistance, and adverse effects. In recent years, a milestone in gynecological cancer therapy has been the approval of antibody-drug conjugates (ADCs). In this review, we provide a comprehensive overview of the structural features, mechanisms of action, and molecular characteristics of ADCs that have been approved and are currently under development. Their clinical applications and associated challenges have also been highlighted. Finally, we discuss the prospects of ADCs in the treatment of gynecological cancers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development and application of antibody-drug conjugates in gynecological cancers

  • 期刊论文

  • 发表日期：

    2025年11月5日

查看全文
  • Ruxi Zheng,
  • Jiaojiao Zhang,
  • Jianwei Zhou,
  • Zhigang Zhang,
  • Mengke Niu,
  • Jing Fei,
  • Kongming Wu,
  • Ming Yi,
  • Tianye Li

摘要

Gynecological cancer poses a serious threat to women’s health. Despite significant advances in immunotherapy and targeted therapeutic strategies for gynecological cancers, substantial challenges persist, including limited response rates, inevitable resistance, and adverse effects. In recent years, a milestone in gynecological cancer therapy has been the approval of antibody-drug conjugates (ADCs). In this review, we provide a comprehensive overview of the structural features, mechanisms of action, and molecular characteristics of ADCs that have been approved and are currently under development. Their clinical applications and associated challenges have also been highlighted. Finally, we discuss the prospects of ADCs in the treatment of gynecological cancers.